PMPRB Framework modernization is underway with significant changes pending to both the Patented Medicine’s Regulations and PMPRB Pricing Guidelines. Gather insights on:
Discover what regulatory changes can mean to your market access strategy.
Changes to the Patented Medicines Regulations and PMPRB Pricing Guidelines mean the adoption of new strategies for market access professionals. After PMPRB’s keynote, discuss strategies to:
Develop new market access strategies to adapt to regulatory changes.
The Regulatory Review of Drugs and Devices (R2D2) initiative changes how you work. Review the objectives of this initiative to improve access to treatment. Stay up-to-date on:
Analyse the R2D2 initiative to enhance access to treatment.
Governments, payers and healthcare’s other stakeholders increasingly look to incorporate data to support decision-making. Explore innovation in Real-World Evidence to improve the value, efficacy and impact of medicines. Take away strategies to:
Prove and improve the value, efficacy and impact of your medicines with RWE.
Regional health authorities are working to improve alignment with public drug plans and utilize the best available evidence when reviewing hospital only drugs. Clarify how Alberta approaches DTC processes, what information about system costs AHS uses to make decisions and evaluate some of the work that has been done to date to improve your market access strategy. Gain insights to:
Evaluate the evolution of decision-making at the regional level and its effects on your organization.
Reconciling the urgency of patient need with a thorough HTA process is a growing a challenge. Explore what patients expect from you to improve patient outcomes. Gain insights to:
Ensure the patients are at the centre of your strategic planning.
There is a lot of buzz around harnessing historic trends and patterns in patient data - is it hype or reality? Many wonder if it will impact PSP design and implementation and whether patients will benefit. Take away a plan to understand:
Understand how predictive analytics in patient support could help your organization.
Complying with Provincial expectations for product listing agreements is critical to your market access strategy. Ensure you meet the needs of key provinces to get your product to market. Gain practical tips to:
Gain practical insights on how to list your drug with a province.
The private payer landscape is undergoing significant changes that will impact patient access and how medications are reimbursed. Strengthen your market access strategy with insights into emerging trends in the private payer landscape. Source critical information to:
Integrate the employer’s outlook into your market access strategies.
Small markets can impede the development of orphan drugs, but collaboration can alleviate some restraints. Build partnerships to develop your new products and secure revenue opportunities. Build a roadmap to:
Work with your stakeholders to increase patient access to treatments.
CADTH CDR made changes to improve transparency and HTA timelines. Explore what these changes can do to streamline your submissions. Source intelligence on:
Align with new CDR guidelines to advance your approval processes.
The most extensive changes to medicines policy for the last five years are being introduced in the UK:
Unleash the full potential of market access solutions for your company by taking a page out of international playbooks.
Plan designs impact drug utilization by influencing patient behaviour. Identify new trends in plan design and their impact on your market access strategy. Discover insights to:
Utilize experienced perspectives on data integration to bolster your company’s access strategies
The pCPA changed notably in the past few years and its approach to negotiation has evolved. Reassess your expectation and improve your submissions. Source Intelligence to:
Review changes at pCPA to enhance your submission process.
The growing transparency at CADTH and shrinking hospital budgets are changing the perspective of GPOs. Adapt to GPO’s approach to ensure your access to hospital and community care. Create a roadmap to:
Work with your stakeholders to increase patient access to treatments.
The next wave of biosimilars is entering the Canadian market and present unique considerations not part of the current landscape. Avoid silos and discover how to develop an interconnected policy approach with different pan-Canadian system leaders and payer organizations. Learn about the considerations associated with institutionally-based products such as oncology therapeutic biosimilars, including:
Assess how the market and policies are evolving as the first Oncology therapeutic biosimilars pass through the reimbursement system.
As private coverage becomes increasingly complex, Patient Support Programs (PSPs) are a valuable tool to assist patients’ access to your medications. Optimize your programs to ensure they are aligned and integrated with private payer programs to maximize patient access. Gain insights to:
Leverage PSPs to improve your private payer programs.
The pan-Canadian Pharmaceutical Alliance (pCPA) has established their office and become a formal process for getting new drugs to the market. Source insights to manage and optimize your submission. Tap into both public and private perspectives in this interactive workshop and walk away with knowledge to:
Develop your successful pCPA strategy through this hands-on interactive workshop.